Compare Merck & Co., Inc. (MRK) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Nomura Holdings Inc — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while Nomura Holdings Inc trades at $9.59 (market cap $27.55B). The key difference: Merck & Co., Inc. is far larger — about 12.8× Nomura Holdings Inc's market cap, and Nomura Holdings Inc pays the higher dividend (3.4%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Nomura Holdings Inc for 55 Days on average.
| MRK | NMR | |
|---|---|---|
Market Cap | $351.28B | $27.55B |
Volume | 7,969,665 | 782,470 |
Sector | Health | Financials |
52-Week High | $156.43 | $10.86 |
52-Week Low | $82.49 | $6.73 |
Typical Hold Time | 98 Days | 55 Days |
Enterprise Value | $398.04B | $38.54T |
Dividend Yield | 2.39% | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
Nomura Holdings (NMR) trades at $9.54, up 0.1% today, with a bearish technical signal but strong fundamental metrics including a P/E of 11.33 and net income margin of 20.4%. Revenue grew to $1.66 trillion in 2025, and the stock has recently been added to Zacks Strong Buy lists, indicating positive momentum recognition. Cash flow trends show variability, with 2025 net cash flow positive at $126.42 billion despite negative operating cash flow.
The outlook is mixed; solid profitability and low valuation ratios support upside potential, but recent earnings misses and a bearish technical backdrop pose near-term risks. Analyst consensus leans hold (66.67%), suggesting cautious optimism. Key risks include debt level increases and macroeconomic sensitivity affecting Japan's bond market, as noted by Nomura's own analysis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
